Lipogems To Launch Study to Treat Knee Osteoarthritis

Lipogems was granted unconditional approval by FDA to conduct an Investigational Device Exemption (IDE) study for the treatment of knee osteoarthritis (OA) compared to corticosteroids for a period of 12 months.

Lipogems is a market-stage medical device company that received FDA 510(k) clearance in 2014 for their device, which is used to process...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0